GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
H

HK Inno.N 195940.KQ · KRW

Health Care · KOSDAQ · 🇰🇷 South Korea

Compare

34,850

-2.38%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About HK Inno.N

Its shares trade on KOSDAQ under the ticker 195940.KQ. It has been listed since 9 August 2021. In the fiscal year to 31 December 2025, it reported revenue of ₩1.06trn and net income of ₩75.70bn. At that date it held total assets of ₩2.10trn and shareholders' equity of ₩1.33trn.

HK inno.N Corp. engages in the provision of healthcare services. The company is headquartered in Chungju, Chungcheongbuk-Do. The company went IPO on 2021-08-09. The firm operates its business through three segments. The Prescription Drug segment is engaged in the manufacture and sale of hormone drugs, anticancer drugs, high blood pressure drugs, gastroesophageal reflux disease drugs, blood nutrient supplies, the circulatory system and others. The Health Beauty and Beverage (HB&B) segment is engaged in the manufacture and sale of products such as hangover relieving products, as well as health drinks and food products. The Other segment is engaged in the trademark royalties business and other services. The firm sells its products within domestic market and to overseas markets.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
9 Aug 2021
Employees
1,710
Website
inno-n.com ↗

Leadership

Pay as last reported

  • Mr. Dal Won KwakChief Executive Officer, Vice President, Director
  • Mr. Sang Hyeon YoonVice Chairman
  • Mr. Mu Jeong SeoVice President, Director
  • Heon Jong ChiManaging Director
  • Mr. Geun Seok SongManaging Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • HK Inno.N Corp manufactures hormone drugs and anticancer drugs in the Prescription Drug segment.
  • The HB&B segment offers hangover relieving products and health drinks for domestic sales.
  • The company employs 1,710 full-time employees across three business segments.

Weaknesses

  • The Prescription Drug segment focuses on hormone drugs with limited product diversity.
  • The HB&B segment relies on hangover relieving products with narrow market appeal.
  • The Other segment generates revenue from trademark royalties with minimal growth potential.

Opportunities

  • Expanding the Prescription Drug segment into anticancer drugs for global markets.
  • Increasing HB&B segment sales in overseas markets for health drinks and food products.
  • Growing the Other segment through new trademark royalty agreements.

Threats

  • Competition in the Prescription Drug segment from established pharmaceutical firms.
  • Regulatory changes affecting the HB&B segment's hangover relieving products.
  • Market saturation in the Other segment's trademark royalty business.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.